The treatment landscape for PAH has evolved dramatically over the past 30 years. 3
Medications targeting the endothelin, nitric oxide, and prostacyclin pathways have been …

In the last 15 years, 12 specific therapies have been approved for PAH. These therapies
target three separate pathogenic pathways [the endothelin (ET), nitric oxide (NO) and …

Pulmonary arterial hypertension (PAH) includes a series of clinical conditions characterized
by progressive increase of pulmonary vascular resistance (PVR) leading to right heart failure …

Pulmonary arterial hypertension (PAH) is a severe condition resulting from obstructive
remodeling of the distal pulmonary arteries. 1 Narrowing of the pulmonary arteries leads to …

Abstract Background and Aims Effective therapies that target three main signalling pathways
are approved to treat pulmonary arterial hypertension (PAH). However, there are few large …

Pulmonary arterial hypertension (PAH) is a severe disease characterised by a progressive
increase of pulmonary pressure and resistance leading to right heart failure. PAH is …

Background No meta-analysis for indirect comparisons has been conducted to study the
effectiveness of treatments for pulmonary arterial hypertension (PAH). Methods Our search …

Pulmonary arterial hypertension (PAH) is a devastating disease that leads to right heart
failure and premature death. Historically, we are restricted by limited options for drug …

Until in the early nineties, pulmonary arterial hypertension (PAH) was a uniformly fatal
disease, with a median life expectancy of∼ 2.5 years. Uncontrolled studies showed that a …

In the past 2 decades, major changes have occurred in the epidemiological and treatment
landscape of pulmonary arterial hypertension (PAH). Previously regarded as a disease of …